

- 1) Amsterdam JD, Fawcett J, Quitkin FM et al. Fluoxetine and Norfluoxetine Plasma Concentrations in Major Depression: A Multicenter Study. *Am J Psychiatry*. 1997;154(7):963-969
- 2) Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. *Psychopharmacol Bull*. 1990;26(1):18-24
- 3) Benazzi FA. A "therapeutic window" with citalopram in a case of depression. *Pharmacopsychiatry*. 1996;29:42
- 4) Bjerkenstedt L, Flyckt L, Overo KF et al. Relationship Between Clinical Effects, Serum Drug Concentration and Serotonin Uptake Inhibition in Depressed Patients Treated with Citalopram. *Eur J Clin Pharmacol*. 1985;28:553-557
- 5) Citrome L, Volavka J. Optimal Dosing of Atypical Antipsychotics in Adults: A review of the Current Evidence. *Harvard Rev Psychiatry*. 2002;10:280-291
- 6) Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. *Journal of Affective Disorder*. 1990;18:289-299
- 7) Dufour H, Bouchacourt M, Thermo P et al. Citalopram—a highly selective 5-HT uptake inhibitor—in the treatment of depressed patients. *Int Clin Psychopharmacol*. 1987;2:225-237
- 8) Fabre LF, Abuzzahab FS, Amin M et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. *Biol Psychiatry*. 1995 Nov 1;38(9):592-602
- 9) Gerstenberg G, Aoshima T, Fukasawa T et al: Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite acid in Japanese depressed patients. *Psychopharmacology* 167:443-448, 2003
- 10) Goodnick PJ. Pharmacokinetic optimization of therapy with newer antidepressants. *Clin Pharmacokinet* 1994;27(4):307-30
- 11) Haetter S, Wetzel H, Hammes E et al. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. *Pharmacopsychiatry*. 1998;31(5):199-200
- 12) Hasegawa M, Gutierrez-Esteinou R, Way L et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. *J Clin psychopharmacol*. 1993;13:383-390
- 13) 広兼元太、染矢俊幸、柴崎守和ほか：プロムペリドール代謝の個体差と臨床症状

改善度との関連. 神経精神薬理, 1997;19:39-49

- 1 4) Hirokane G, Someya T, Takahashi S et al. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. *Ther Drug Monit.* 1999;21(1):82-86
- 1 5) Kasper S, Dotsch M, Kick H et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. *Eur Neuropsychopharmacol.* 1993;3(1):13-21
- 1 6) Kelly MW, Perry PJ, Holstad SG, Garvey MJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. *Drug Monit.* 1989;11(2):165-170
- 1 7) Koran LM, Cain JW, Dominguez RA et al. Are Fluoxetine Plasma Levels Related to Outcome in Obsessive-Compulsive Disorder? *Am J Psychiatry.* 1996;153(11):1450-1453
- 1 8) Kronig MH, Munne RA, Szymanski S et al. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. *Am J Psychiatry.* 1995;152:179-182
- 1 9) Kuhs H, Schlake HP, Rolf GAE. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. *Acta Psychiatr Scand.* 1992;85(5):364-369
- 2 0) Laursen AL, Mikkelsen PL, Rasmussen S et al. Paroxetine in the treatment of depression — a randomized comparison with amitriptyline. *Acta Psychiatr Scand.* 1985;71(3):249-255
- 2 1) Magliozzi JR, Hollister LE, Arnold KV et al. Relationship of serum haloperidol level to clinical response in schizophrenic patients. *Am J Psychiatry.* 1981;138:365-367
- 2 2) Montgomery SA, Baldwin D, Shah A et al. Plasma-level response relationships with fluoxetine and zimelidine. *Clin Neuropharmacol.* 1990;13 Suppl 1:S71-S75
- 2 3) Nathan RS, Perel JM, Pollock BG, Kupfer DJ. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. *J Clin Psychiatry.* 1990;51(9):367-372
- 2 4) Norman TR, Gupta RK, Burrows GD et al. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. *Int Clin Psychopharmacol.* 1993 Spring;8(1):25-29
- 2 5) Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response : acute phase results of the North American Olanzapine Trial.

- J Clin Psychopharmacol 2001;21:14-20
- 2 6) Perry PJ, Miller DD, Arndt SV et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-235
 - 2 7) Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressants response and tricyclic antidepressants plasma concentrations. Clin Pharmacokinet 1987;13:381-92
 - 2 8) Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenics. J Clin Psychopharmacol 1997;17:472-7
 - 2 9) Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther. Drug Monit. 2000;22(2):143-154
 - 3 0) Riedel M, Schwarz MJ, Strassnig M et al. Risperidone plasma level, clinical response and side-effect. Eur Arch Psychiatry Clin Neurosci. 2004
 - 3 1) Sato S, Someya T, Shioiri T et al. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. Pharmacol Toxicol. 2000;86(3):145-148
 - 3 2) Sawamura K, Suzuki Y, Soyema T. Effect of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60:553-557
 - 3 3) Shimoda K, Minowada T, Noguchi T et al: Inter-individual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population. J Clin Psychopharmacol. 1993;13:181-188
 - 3 4) Shimoda K, Morita S, Hirokane G et al: Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol. 2000;86(6):245-249
 - 3 5) Shimoda K, Someya T, Yokono A et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002;22(4):371-378
 - 3 6) Small JG, Hirsch SR, Arvanitis LA et al. Quetiapine in patients with schizophrenia: a high and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;549-557
 - 3 7) Someya T, Muratake T, Hirokane G et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. J Clin Psychopharmacol. 2000;20(2):175-180
 - 3 8) Someya T, Shimoda K, Suzuki Y et al. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.

Neuropsychopharmacology. 2003;28(8):1501-1505

- 3 9) Spina E, Avenoso A, Facciola G et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic in patients with schizophrenia resistant to conventional neuroleptics. *Psychopharmacology*. 2000;148:83-89
- 4 0) Spina E, Avenoso A, Facciola G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. *Psychopharmacology* 2001;153:238-43
- 4 1) 鈴木雄太郎、染矢俊幸. 抗うつ薬と反応性予測—SSRIを中心に—. *臨床精神薬理*. 2003;6: 297-305
- 4 2) 高木哲郎、渡部健一郎、猪山茂ほか：精神分裂病に対する bromperidol の治療効果と血中濃度. *臨床と研究*. 1986;66:294-300
- 4 3) Van Puttern T, Marder SR, Wrisling WC et al: Neuroleptic plasma levels. *Schizophr Bull*. 1991;17:197-216
- 4 4) VanderZwaag C, McGee M, McEvoy JP et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum ranges. *Am J Psychiatry*. 1996;153:1579-1584
- 4 5) Yasui-Furukori N, Mihara K, Kondo T et al. Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9-hydroxyrisperidone in Japanese Patients with Schizophrenia. *J Clin Pharmacol*. 2003;43:122-127
- 4 6) Yokono A, Morita S, Someya T et al. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. *J Clin Psychopharmacol*. 2001;21(6):549-555





Fig. 3 Relationship between Dose and Plasma Level of FLV

☒ 1



☒ 2





Fig. 1 Accumulated remission rate
- Relationship with plasma FLV Level when remitted -

図 3

図1. プロムペリドールの投与量と血中濃度の関係



(広兼元太ほか：神経精神薬理 19：39-49, 1997.)

図 4